CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive that an abstract on the potential of its drug candidate leronlimab for the prevention of HIV has been accepted for presentation at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. Pourhassan says acceptance of the abstract as late-breaking describes leronlimab’s significant assistance in HIV prevention.
Full interview: CytoDyn to present HIV prevention data at HIV research meeting in Boston
Quick facts: CytoDyn Inc.
Price: 2.95 USD
Market Cap: $1.27 billion
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE